Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells.

Li, Bohui; Kong, Xiangjun; Post, Harm; Raaijmakers, Linsey; Peeper, Daniel S; Altelaar, Maarten

Li, Bohui; Kong, Xiangjun; Post, Harm; Raaijmakers, Linsey; Peeper, Daniel S; Altelaar, Maarten.

Afiliación

Li B; Biomolecular Mass Spectrometry and Proteomics Group, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht 3584 CH, The Netherlands.
Kong X; Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Post H; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Raaijmakers L; Biomolecular Mass Spectrometry and Proteomics Group, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht 3584 CH, The Netherlands.
Peeper DS; Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands.
Altelaar M; Biomolecular Mass Spectrometry and Proteomics Group, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht 3584 CH, The Netherlands.

J Proteome Res ; 20(9): 4381-4392, 2021 09 03.

Article en En | MEDLINE | ID: mdl-34343000

Asunto(s)

Melanoma; Preparaciones Farmacéuticas; Línea Celular Tumoral; Resistencia a Antineoplásicos; Glucógeno Sintasa Quinasa 3; Humanos; Melanoma/tratamiento farmacológico; Melanoma/genética; Inhibidores de Proteínas Quinasas/farmacología; Proteómica; Proteínas Proto-Oncogénicas B-raf/genética

Palabras clave

BRAF-resistant; EMT; ERK1/MAPK3; ERK2/MAPK1; melanoma; phosphoproteomics; proteomics

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Preparaciones Farmacéuticas / Melanoma Límite: Humans Idioma: En Revista: J Proteome Res Asunto de la revista: BIOQUIMICA Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google